Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

Authors:
Janelle M Hoskins
Janelle M Hoskins
University of North Carolina
United States
Eugenio Marcuello
Eugenio Marcuello
Hospital de la Santa Creu i Sant Pau
Albert Altes
Albert Altes
Universitat Internacional de Catalunya
Sharon Marsh
Sharon Marsh
Washington University School of Medicine
United States
Taylor Maxwell
Taylor Maxwell
Washington University School of Medicine
United States
Robert Culverhouse
Robert Culverhouse
Washington University School of Medicine
United States

Clin Cancer Res 2008 Mar;14(6):1788-96

Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Purpose: Irinotecan is an important drug for the treatment of solid tumors. Although genes involved in irinotecan pharmacokinetics have been shown to influence toxicity, there are no data on pharmacodynamic genes. CDC45L, NFKB1, PARP1, TDP1, and XRCC1 have been shown to influence the cytotoxic action of camptothecins, including irinotecan. Polymorphisms in the drug target of camptothecins, topoisomerase I (TOP1), and downstream effectors may influence patient outcomes to irinotecan therapy. We undertook a retrospective candidate gene haplotype association study to investigate this hypothesis.

Experimental Design: Haplotype compositions of six candidate genes were constructed in European (n = 93), East Asian (n = 94), and West African (n = 95) populations. Haplotype-tagging single nucleotide polymorphisms (htSNP) were selected based on genealogic relationships between haplotypes. DNA samples from 107 European, advanced colorectal cancer patients treated with irinotecan-based regimens were genotyped for htSNPs as well as three coding region SNPs. Associations between genetic variants and toxicity (grade 3/4 diarrhea and neutropenia) or efficacy (objective response) were assessed.

Results: TOP1 and TDP1 htSNPs were related to grade 3/4 neutropenia (P = 0.04) and response (P = 0.04), respectively. Patients homozygous for an XRCC1 haplotype (GGCC-G) were more likely to show an objective response to therapy than other patients (83% versus 30%; P = 0.02). This effect was also seen in a multivariate analysis (odds ratio, 11.9; P = 0.04). No genetic variants were associated with diarrhea.

Conclusions: This is the first comprehensive pharmacogenetic investigation of irinotecan pharmacodynamic factors, and our findings suggest that genetic variation in the pharmacodynamic genes may influence the efficacy of irinotecan-containing therapies in advanced colorectal cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1472DOI Listing

Still can't find the full text of the article?

Sign up to send a request to the authors directly.
March 2008
12 Reads

Publication Analysis

Top Keywords

pharmacodynamic genes
12
objective response
8
grade 3/4
8
colorectal cancer
8
advanced colorectal
8
genetic variants
8
cancer patients
8
irinotecan
6
genes
5
influence
5
polymorphisms htsnp
4
htsnp selected
4
002 multivariate
4
single nucleotide
4
multivariate analysis
4
haplotype-tagging single
4
30% 002
4
nucleotide polymorphisms
4
based genealogic
4
haplotypes dna
4

Altmetric Statistics

Similar Publications

Ixazomib: a novel drug for multiple myeloma.

Expert Rev Hematol 2018 Oct;11(10):761-771

a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Read More

View Article
October 2018
5 Reads

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.

J Med Virol 2018 May 1;90(5):907-918. Epub 2018 Feb 1.

Evidence Based Medicine Research Group & Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam.

Daclatasvir, asunaprevir (ASV), and beclabuvir (BCV) are direct-acting antivirals (DAAs) for patients with hepatitis C virus genotype 1 infection. This systematic review and meta-analysis investigating the efficacy and safety of this three-drug combination in HCV genotype 1 infection. Eleven electronic search engines were searched for relevant publications. Read More

View Article
May 2018
15 Reads
2.35 Impact Factor

Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy.

Tumour Biol 2015 Aug 5;36(8):5727-42. Epub 2015 Jul 5.

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic approaches. There are several nanoparticles (NPs) which can act as a potent drug carrier for cancer therapy. However, the specific drug delivery to cancer cells is an important issue which should be considered before designing new NPs for in vivo application. Read More

View Article
August 2015
35 Reads
6 PubMed Central Citations(source)
2.84 Impact Factor

Actinomycosis of the appendix and pelvis: a case report.

J Reprod Med 2008 Sep;53(9):711-3

Department of Obstetrics and Gynecology, Alexandra General Hospital, Athens, Greece.

Background: Actinomycosis is a chronic infection caused by Actinomyces israeli, a gram-positive saprophytic anaerob, a normal inhabitant of the upper intestinal tract.

Case: We report a case of a 35-year-old female with an intrauterine device (IUD) who appeared in the emergency department with clinical characteristics of appendicitis. Ultrasound and computed tomography were performed, revealing an ovarian tumor formation and acute appendicitis. Read More

View Article
September 2008
5 Reads
5 PubMed Central Citations(source)
0.58 Impact Factor